About: Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys
Creator	Du, Lanying Guo, Yan Jiang, Shibo Zhao, Guangyu Zhou, Yusen Zeng, Lin Sun, Shihui Li, Yan Guo, Renfeng Wang, Renxi Li, Junfeng Yu, Hong Kou, Zhihua Liu, Chenfeng Zhou, Xiaojun Fan, Wei Habel, Maria Riedemann, Niels Schneider, Conny
Source	Medline; PMC
abstract	Background. Patients infected with influenza A(H7N9) virus present with acute lung injury (ALI) that is due to severe pneumonia and systemic inflammation. It is often fatal because there are few effective treatment options. Complement activation has been implicated in the pathogenesis of virus-induced lung injury; therefore, we investigated the effect of targeted complement inhibition on ALI induced by H7N9 virus infection. Methods. A novel neutralizing specific antihuman C5a antibody (IFX-1) was used. This antibody blocked the ability of C5a to induce granulocytes to express CD11b while not affecting the ability of C5b to form the membrane attack complex. African green monkeys were inoculated with H7N9 virus and treated intravenously with IFX-1. Results. The virus infection led to intense ALI and systemic inflammatory response syndrome (SIRS) in association with excessive complement activation. Anti-C5a treatment in H7N9-infected monkeys substantially attenuated ALI: It markedly reduced the lung histopathological injury and decreased the lung infiltration of macrophages and neutrophils. Moreover, the treatment decreased the intensity of SIRS; the body temperature changes were minimal and the plasma levels of inflammatory mediators were markedly reduced. The treatments also significantly decreased the virus titers in the infected lungs. Conclusions. Antihuman C5a antibody treatment remarkably reduced the ALI and systemic inflammation induced by H7N9 virus infection. Complement inhibition may be a promising adjunctive therapy for severe viral pneumonia.
has issue date	2015-02-15(xsd:dateTime)
bibo:doi	10.1093/cid/ciu887
bibo:pmid	25433014
has license	no-cc
sha1sum (hex)	a7d1aa453c98881cc2669c24d623ae1365c22191
schema:url	https://doi.org/10.1093/cid/ciu887
resource representing a document's title	Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys
has PubMed Central identifier	PMC7112341
has PubMed identifier	25433014
schema:publication	Clin Infect Dis
resource representing a document's body	covid:a7d1aa453c98881cc2669c24d623ae1365c22191#body_text
is schema:about of	named entity 'VIRUS INFECTION' named entity 'pneumonia' named entity 'ALI' named entity 'OUTCOME' named entity 'INFECTED' named entity 'H7N9' named entity 'BACKGROUND' named entity 'INDUCED' named entity 'TREATMENT OPTIONS' named entity 'FATAL' named entity 'ACUTE LUNG INJURY' named entity 'SYSTEMIC INFLAMMATION' named entity 'PATHOGENESIS' named entity 'INFLUENZA A' named entity 'COMPLEMENT ACTIVATION' named entity 'TREATMENT' named entity 'PATIENTS' named entity 'IMPROVES' named entity 'C5A' named entity 'INHIBITION' named entity 'EFFECTIVE' named entity 'LUNG INJURY' named entity 'INVESTIGATED' named entity 'AFRICAN GREEN MONKEYS' named entity 'ANTIBODY' named entity 'H7N9' named entity 'SEVERE PNEUMONIA' named entity 'COMPLEMENT' named entity 'TARGETED' named entity 'VIRUS INFECTION' named entity 'DUE TO' named entity 'VIRUS PRESENT' named entity 'VIRUS' named entity 'EFFECT' covid:arg/a7d1aa453c98881cc2669c24d623ae1365c22191 named entity 'pathogenesis' named entity 'investigated' named entity 'effective' named entity 'ALI' named entity 'H7N9' named entity 'systemic inflammation' named entity 'pathogenesis' named entity 'ALI' named entity 'Complement activation' named entity 'H7N9' named entity 'neutrophils' named entity 'Antibody' named entity 'H7N9' named entity 'synergistic' named entity 'safety profile' named entity 'inflammatory cytokines' named entity 'infection' named entity 'systemic inflammation' named entity 'Complement' named entity 'mAb' named entity 'epithelial cells' named entity 'C5a' named entity 'membrane attack complex' named entity 'complement activation' named entity 'viral titers' named entity 'IL-6' named entity 'protein' named entity 'SARS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software